Acute renal failure after Crotalus durissus snakebite: A prospective survey on 100 patients  by Pinho, Fabia M.O. et al.
Kidney International, Vol. 67 (2005), pp. 659–667
Acute renal failure after Crotalus durissus snakebite:
A prospective survey on 100 patients
FA´BIA M.O. PINHO, DIRCE M.T. ZANETTA, and EMMANUEL A. BURDMANN
Division of Nephrology, University of Sa˜o Paulo Medical School, Sa˜o Paulo, and Hospital de Doenc¸as Tropicais (Tropical Diseases
Hospital) of Goiaˆnia, Brazil; Department of Epidemiology and Public Health; and Division of Nephrology, Sa˜o Jose´ do Rio Preto
Medical School, Brazil
Acute renal failure after Crotalus durissus snakebite: A
prospective survey on 100 patients.
Background. Acute renal failure (ARF) is the main cause of
death after the South American crotalid snakebite. The aim of
this study was to assess the prevalence, risk factors, and charac-
teristics of Crotalus durissus venom-induced ARF.
Methods. One hundred cases of Crotalus durissus bite were
studied from hospitalization to discharge or death. Creatinine
clearance (GFR) <60 mL/min/1.73m2 in the first 72 hours after
snakebite was defined as ARF. Data are expressed as median
(range of variation) or%, and were analyzed by univariate anal-
ysis and logistic regression.
Results. Twenty-nine patients developed ARF. Of those, 24%
required dialysis and 10% died. ARF patients had smaller body
surface [1.55 (0.6–2.3) vs. 1.7 (0.6–2.1) m2, P = 0.0097], received
antivenom (AV) later [12 (2–48) vs. 2 (1–14) hours, P < 0.0001],
received more AV [190 (90–536) vs. 158 (75–500) mg/m2,
P < 0.0001], presented lower diuresis at admission [62 (0–182)
mL/hr vs. 100 (25–325) mL/hr, P = 0.0004], and showed a strik-
ing creatine kinase (CK) increase [50,250 (69–424,120) vs. 1108
(88–133,170) U/L, P < 0.0001]. Age <12 years (OR 5.6, P =
0.026), time for AV >2 hours (OR 11.1, P = 0.032), CK at ad-
mission >2000 U/L (OR 12.7, P = 0.0009) were identified as in-
dependent risk factors for ARF, whereas diuresis at admission
>90 mL/hr (OR 0.20, P = 0.014) was an independent protector
factor.
Conclusion. C. durissus venom-induced ARF had high preva-
lence (29%). Delay for AV treatment, CK at admission
>2000 U/L, and age <12 years were independent risk factors
for ARF development. Diuresis at admission >90 mL/hr was a
protective factor.
Poisonous snakebites are a serious health challenge in
tropical regions due to their incidence, morbidity, and
mortality [1, 2]. The World Health Organization (WHO)
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estimates there are approximately 125,000 deaths out of
2,500,000 poisonous snakebites a year worldwide [2].
In Brazil, there are 20,000 poisonous snakebites a year,
a mean incidence of 13.5 bites/100,000 inhabitants and a
mortality rate of about 0.45% [3]. The Crotalus gender,
of the Viperidae family and Crotalinae subfamily, is rep-
resented in Brazil by a single species, Crotalus durissus,
or the South American rattlesnake. It is responsible for
7.7% of the notified cases, and for a mortality rate of
1.9%, the greatest among all Brazilian poisonous snakes
[3].
The crotalic venom is a complex mixture of enzymes,
toxins, and peptides. The main identified toxins are cro-
toxin, crotamine, giroxin, convulxin, and an enzyme simi-
lar to thrombin [4, 5]. Crotoxin is responsible for the high
toxicity of the venom [5] and has neurotoxic [6], myotoxic
[7–10], and nephrotoxic [11–13] activity.
The clinical picture of C. durissus snakebite is charac-
terized by mild local injury and systemic manifestations,
which are frequently severe. Eyelid ptosis, blurred vision,
and/or double vision, ophthalmoplegia, and paralysis of
facial muscles are examples of the venom neurotoxic ac-
tivity. Its myotoxic action induces rhabdomyolysis, char-
acterized by generalized myalgia and myoglobinuria. The
coagulant activity triggered by the thrombin-like enzyme
may lead to afibrinogenemia and blood incoagulability in
40% to 50% of the cases [1, 3].
Acute renal failure (ARF) is the major complication
in patients surviving the initial effects of C. durissus en-
venomation, and is considered the major death cause in
these accidents [14, 15]. The crotalid accident is approxi-
mately 10 times less frequent than the bothropic, but the
absolute number of ARF cases reported in literature with
both snake genders is similar [16]. Recent experimental
studies suggest the pathogenesis of crotalid-induced ARF
is related to rhabdomyolysis, renal vasoconstriction, and
a direct nephrotoxic effect of the venom [11–13, 17, 18].
Although the reported prevalence of ARF after C.
durissus snakebite is high [1, 19, 20], all available stud-
ies are retrospective and used parameters with poor
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sensitivity, such as serum creatinine [15, 19, 20], or that
were not very specific, such as diuresis [1, 14, 21, 22], to
evaluate renal function.
The objective of this study was to assess the prevalence,
risk factors, and characteristics of ARF after envenoma-
tion by the South American crotalid.
METHODS
Victims of C. durissus snakebite admitted at the Hospi-
tal de Doenc¸as Tropicais (HDT), Goiaˆnia, Goia´s (GO),
were prospectively studied. HDT is a reference center
for the treatment of snake envenomation in the State of
Goia´s, Brazil.
The diagnosis was based on the snake identification
and/or by a clinical picture consistent with C. durissus
envenomation within the first 24 hours after hospitaliza-
tion. A typical clinical picture was defined as the pres-
ence of neurotoxic face (lid ptosis, flaccid paralysis of
facial muscles, ophthalmoplegia), blurred and/or double
vision, myalgia, and mild injury at the bite site.
Acute renal failure (ARF) was defined as endogenous
creatinine clearance (GFR) <60 mL/min/1.73m2 in the
first 72 hours after envenomation with subsequent recov-
ery of GFR. Patients who did not improve their GFR
were carefully screened, and if there was clinical and/or
laboratory evidence of chronic kidney disease they were
excluded from the analysis. Chronic kidney disease was
defined as baseline serum creatinine (previous to the ac-
cident) over 2 mg/dL, renal ultrasound with decreased
kidneys or loss of the corticomedullary distinction, and/or
history of active or past renal disease.
The study was approved by the Ethics Committees of
the Tropical Diseases Hospital of Goiaˆnia and Hospital
das Clı´nicas, University of Sa˜o Paulo Medical School. Pa-
tients were only included in the study after signing the in-
formed consent. If the patient was younger than 18 years
of age, informed consent was signed by the legal guardian.
All of the patients received specific crotalid antivenom
(Instituto Butantan, Sa˜o Paulo, Brazil) at HDT admis-
sion if adequate treatment had not been carried out pre-
viously. The crotalid antivenom (CAV) was administered
intravenously, following the dosages recommended by
the Health Ministry (HM), according to the classifica-
tion of the accident (Table 1) [3]. Patients with changes
in coagulation time 12 hours after antivenom administra-
tion received an additional CAV dose of 150 mg. Tetanus
prophylaxis was used when required.
At admission, all patients were hydrated with an alka-
linizing solution (500 mL of glucose 5%, 25 mL of man-
nitol 20%, 10 mL of sodium chloride 20%, and 20 mL of
sodium bicarbonate 8.4%), 3 to 6 L/day, according to clin-
ical picture. This solution was used to prevent renal injury
by rhabdomyolysis. If the urinary flow remained satisfac-
tory (1–2 mL/kg/hr in children and 30–40 mL/hr in adults),
Table 1. Classification of crotalid snakebite severity and
recommended antivenom dosage
Classification of the accident (initial evaluation)
Mild Moderate Severe
Myasthenic face and None or Mild or Evident
blurred vision late evident
Myalgia None or Mild Intense
mild
Dark urine None None or little Present
evident
Oliguria or anuria None None None or present
Antivenom mg/no. 75 mg 150 mg 300 mg
of vials
CAV-BCAVa (5 vials) (10 vials) (20 vials)
Modified from National Health Foundation (FUNASA), 2001.
aCAV, crotalid antivenom; BCAV, bothropic-crotalid antivenom.
the solution was maintained for 48 to 72 hours. If the
patient remained oliguric (diuresis <400 mL/day), the
solution was discontinued and furosemide was admin-
istered (240 to 480 mg/day). When necessary (uremia
and/or hypervolemia), intermittent peritoneal dialysis
(IPD) was used.
Clinical parameters
The bite site, severity of envenomation (Table 1), the
type and the amount of antivenom given per body sur-
face, the time elapsing between the snakebite, and the
administration of specific antivenom were evaluated.
Age, gender, body surface, history of chronic diseases
(heart failure, hypertension, or diabetes mellitus), use
of concomitant drugs, hospitalization time, dialysis treat-
ment, and mortality were recorded. The presence of myal-
gia and urinary abnormalities (volume and color), as
assessed by the patient, and the occurrence of lid ptosis
and bleeding were also screened.
Weight (kg), systolic and diastolic blood pressure (mm
Hg), intravenous hydration volume (mL/kg/hr), and di-
uresis (mL/hr) were evaluated daily.
Laboratory evaluation
A blood specimen was collected at admission and daily
until 72 hours after the snakebite. When the patient
developed ARF, blood specimens were collected every
three days until discharge or death. Blood samples were
used to measure sodium, potassium, creatinine, aspar-
tate aminotransferase (AST), alanine aminotransferase
(ALT), creatine kinase (CK), and lactic dehydrogenase
(LDH) (Autoanalyzer Mega Merck 1.0; Merck, Darm-
stadt, Germany), to determine blood coagulation time
(CT) (Lee White Method), hematocrit, hemoglobin, and
platelets (Cell-Dyn 3.000–5.4, San Francisco, CA, USA).
On admission day, urine was collected for at least six
hours to a maximum of 24 hours, depending on the time
of hospitalization and the patient’s urinary volume. It
was then collected and analyzed daily in all patients (12-
hour urinary volume) until 72 hours after the snakebite.
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After that, it was collected every three days until hospital
discharge or death in patients developing ARF. Urinary
volumes at admission and 12-hour urinary volume were
used to dose proteinuria (Bradford modified) and urinary
creatinine (Merck).
A urine sample was collected at admission, daily in the
first 72 hours after the snakebite, and every three days un-
til discharge or death for patients developing ARF. This
sample was used for measurement of sodium, potassium,
and creatinine (Merck), pH (Multistix-Bayer Reagent,
Rosario, Argentina), and for analysis of urinary sediment.
Fractional excretion of sodium (FeNa), fractional ex-
cretion of potassium (FeK), and endogenous creatinine
clearance (GFR) were calculated according to the usual
formulas.
Statistical analysis
Data were expressed as median (variation range) or%.
Patients were analyzed as a group and were later allo-
cated into two groups according to the presence of ARF
(ARF group, with GFR <60 mL/min/1.73m2 in the first
72 hours after envenomation, and non-ARF group with
GFR ≥60 mL/min/1.73m2 in the first 72 hours after en-
venomation). Differences between the two groups were
compared using Fisher test or the Mann-Whitney test, as
indicated.
Dispersion diagrams were shown for time to the ad-
ministration of specific antivenom therapy and CK at ad-
mission.
Differences between GFR at admission, lowest GFR
value, and GFR value at discharge for both groups were
analyzed by analysis of variance (ANOVA), followed by
Tukey’s post-test or by Kruskal-Wallis test, as indicated.
Spearman’s correlation coefficients were calculated for
GFR and time to receive specific antivenom therapy, for
GFR and CK at admission, and for GFR and diuresis at
admission.
Risk factors for ARF were determined by multivari-
ate analysis with logistic regression. The initial model in-
cluded significant variables at the univariate analysis and
clinically significant variables. Two initial models were
developed. Model 1 included age (up to 12 years of
age and above 50 years, reference 13 to 50 years), time
to antivenom (>2 hours), abnormal CT at admission
(>10 minutes), CK at admission (>2000 U/L), and di-
uresis at admission (>90 mL/hr). In model 2, age was
replaced by body surface (BS >1.5 m2). Significant vari-
ables were evaluated by Wald’s test.
P < 0.05 was considered statistically significant.
RESULTS
Analyzed sample
Of the 104 patients hospitalized at the HDT after C.
durissus snakebite from July 1998 to May 2000 and from
August 2001 to March 2003 (43 months), one was ex-
cluded due to previous chronic kidney disease (renal
lithiasis with bilateral hydronephrosis and baseline crea-
tinine >2 mg/dL), and three patients were not followed-
up by the study (percentage of lost cases of 2.9%). The
remaining 100 patients represent 17.3% of all C. duris-
sus snakebites (578 cases) reported in the Health System
of the State of Goia´s in the same period (Toxicological
Information Center, GO).
Time from snakebite to specific antivenom adminis-
tration was three (1–48) hours. Nine patients received
inadequate antivenom in the first medical care, outside
of HDT. Seven were administered bothropic antivenom
(BAV), and two received CAV doses lower than that rec-
ommended by the HM.
Mean age was 30 (3–61) years, 85% were male, and
19% were children ≤12 years. Three patients had a his-
tory of hypertension, and one had a history of diabetes
mellitus. None of them had used nephrotoxic drugs. Mild
inflammation observed at the bite site disappeared within
72 hours of the accident. None of the cases developed in-
fection at the bite site. None of the patients had hypoten-
sion or shock within the first 72 hours after the accident.
Mean hospitalization time was five (2–38) days. There
were three deaths (3%).
Comparison of the ARF and non-ARF groups
Of the 100 patients studied, 29 had GFR <60 mL/
min/1.73m2 in the first 72 hours after the snakebite. Of
these, seven required dialysis (24.1%) and three (10.3%)
died.
All patients who developed ARF were hospitalized
within 72 hours after the snakebite. Of these, 22 (76%)
arrived within 24 hours of the bite, and all of them devel-
oped ARF in this period. The seven remaining patients
who arrived at the hospital 24 to 72 hours after the bite
were already admitted with ARF. Six of the nine (67%)
patients receiving inadequate antivenom developed ARF
(five received BAV and one received insufficient CAV).
Data regarding the accident and antivenom
administration
The time interval between the accident and the admin-
istration of specific antivenom was significantly higher in
the patients who developed ARF than in those who did
not develop it (Fig. 1). There was a higher prevalence of
cases classified as severe in the ARF group and, there-
fore, this group received more antivenom per body sur-
face than the non-ARF group. There was no difference
between both groups regarding the bite site (Table 2).
Patient data
Although ARF patients were younger, this difference
was not statistically significant [24 (3–59) years vs. 32
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Fig. 1. Time interval from snakebite to administration of the specific
antivenom in ARF and non-ARF groups. The horizontal bars indicate
median values.
Table 2. Comparison between the two groups for data regarding the
accident and the patients
ARF Non-ARF
(N = 29) (N = 71) P value
Time to AV hours 12 (2–48) 2 (1–14) <0.0001
Amount of AV/BS 190 (90–536) 158 (75–500) <0.0001
mg/m2
Cases classified as 90 54 0.0005
severe%
Bite of lower 83 78 0.7872
extremities%
Age years 24 (3–59) 32 (3–61) 0.0882
Weight kg 56.3 (14.5–105.0) 64.0 (15.0–95.2) 0.0067
BS m2 1.55 (0.6–2.3) 1.70 (0.6–2.1) 0.0097
Males% 83 86 0.7599
Lid ptosis% 100 70 0.0003
Myalgia% 100 94 0.32
Abbreviations are: AV, antivenom; BS, body surface.
Values expressed as median (variation range) or %.
(3–61) years, P = 0.088]. Of the 19 children (≤12 years) in-
cluded in the study, 11 developed ARF (58%), and of the
81 adults, 18 developed ARF (22%, P = 0.004 adults vs.
children). Weight and body surface (BS) of the patients
with ARF were significantly lower than the patients who
did not develop ARF. Both ARF and non-ARF groups
included more males.
The ARF group had significantly more patient com-
plaints of urinary volume decrease (ARF, 86% vs. non-
ARF, 31%, P < 0.0001) and dark urine (ARF, 83% vs.
P <0.0001
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Fig. 2. Creatine kinase (CK) values at admission in the ARF and non-
ARF groups. The horizontal bars indicate median values.
non-ARF, 49%, P = 0.0032). Lid ptosis and general-
ized myalgia were observed in all patients who developed
ARF.
Both groups had similar systolic [ARF, 120 (90–180)
mm Hg and non-ARF, 120 (100–180) mm Hg, P = 0.8510]
and diastolic [ARF, 80 (60–110) mm Hg and non-ARF,
80 (60–120) mm Hg, P = 0.4312] blood pressure at ad-
mission.
Both groups received similar hydration at admis-
sion [ARF, 3.0 (0.6–10.2) and non-ARF, 3.0 (1.2–15.6)
mL/kg/hr, P = 0.4747] and within the first 72 hours [ARF,
2.6 (0.7–9.6) and non-ARF, 2.2 (1.1–10.5) mL/kg/hr, P =
0.60].
Hospitalization time was longer in the ARF group
[5 (2–38) days] when compared with the non-ARF group
[5 (3–7) days, P = 0.0016].
Patient data are summarized in Table 2.
Laboratory evaluation of rhabdomyolysis
Both groups showed a significant increase of CK serum
levels at admission. However, CK values observed in the
ARF group were significantly higher than those in the
non-ARF, reaching levels 260 times higher than normal
(Fig. 2). Other markers of rhabdomyolysis, such as AST,
ALT, and LDH were also significantly higher at admission
in the ARF group when compared to the non-ARF group
(Table 3).
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Table 3. Comparison of both groups for rhabdomyolysis markers at
admission
ARF Non-ARF
(N = 29) (N = 71) P value
CK U/L 50,250 (69–424,120) 1,108 (88–133,170) <0.0001
AST UI/L 1544 (12–16,170) 60 (13–4170) <0.0001
ALT UI/L 325 (10–3880) 25 (10–854) <0.0001
LDH UI/L 2833 (154–28,990) 384 (180–4673) <0.0001
Abbreviations are: CK, creatine kinase; AST, aminotransferase aspartate;
ALT, aminotransferase alanine; LDH, lactic dehydrogenase; ARF, acute renal
failure. Values expressed as median (variation range).
Table 4. Comparison of renal function data
ARF Non-ARF
(N = 29) (N = 71) P value
Diuresis at admission 62 (0–182) 100 (25–325) 0.0004
mL/hr
Diuresis in the first 90 (0–177) 116 (52–204) 0.0006
3 days mL/hr
GFR at admission 38.6 (0–54.4) 91.6 (61–162.2) <0.0001
mL/min/1.73m2
GFR nadir mL/ 38.6 (0–54.4) 85.4 (61.1–110.2) <0.0001
min/1.73m2
GFR at discharge 87.5 (21.9–104.7) 102.1 (90.7–145) <0.0001
mL/min/1.73m2
FeNa at admission% 2.4 (0.1–19.7) 1.0 (0.2–4.8) <0.0001
Maximum FeNa% 4.1 (0.8–35) 1.9 (0.2–5.5) <0.0001
FeK at admission% 28.3 (8.5–150) 9.8 (0.5–39.6) <0.0001
Maximum FeK% 35.9 (8.5–164) 13.2 (2.4–55) <0.0001
Proteinuria at 34.0 (3.6–160) 9.7 (1.5–95.4) <0.0001
admission mg/
m2/hr
Abbreviations are: GFR, glomerular filtration rate; FeNa, fractional excretion
of sodium; FeK, fractional excretion of potassium; ARF, acute renal failure.
Values expressed as median (variation range).
Hematology and coagulation time
Hematocrit, hemoglobin, and platelet levels at admis-
sion were similar and normal in both groups (data not
shown). Although the CT at admission was abnormal in
83% of the patients in the ARF group and in 51% of the
non-ARF group (P = 0.0033), none of the patients had
hemorrhage.
Renal function
Urinary volume at admission was 62 (0–182) mL/hr
in the ARF group and 100 (25–325) mL/hr in the non-
ARF group (P = 0.0004). When diuresis was compared in
the first 72 hours of treatment, the statistically significant
difference between groups remained. In the ARF group,
only four patients were oliguric and required the use of
diuretics.
GFR at admission, GFR nadir, and GFR at dis-
charge are shown in Table 4. All of the patients in the
ARF group had the lowest GFR values within the first
48 to 72 hours after the accident. Both the ARF and the
non-ARF group presented a GFR at discharge signifi-
cantly higher than the nadir of GFR (Fig. 3). Only five
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Fig. 3. GFR at admission, GFR nadir, and GFR at discharge in the
ARF (A) and non-ARF (B) groups. Data are shown as box and whisker
plots. The lines in the middle and those delimiting the boxes, respec-
tively, indicate median and 25th and 75th percentile values.
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Fig. 4. Negative correlation between time to administration of the spe-
cific antivenom and GFR at admission.
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at admission.
of the 29 patients with ARF did not increase their GFR
over 60 mL/min/1.73m2 during hospitalization (actually,
23 were discharged with GFR over 80 mL/min/1.73m2).
Among these five patients, three died, and the two oth-
ers were discharged with GFR of 21.9 mL/min/1.73m2
(nadir 0 mL/min/1.73m2) and 50.7 mL/min/1.73 m2 (nadir
13.5 mL/min/1.73m2), respectively. None of these five pa-
tients presented clinical or laboratory evidence of chronic
kidney disease. All patients in the non-ARF group were
discharged with GFR over 90 mL/min/mL/min/1.73m2.
GFR at admission had a significant negative correla-
tion with time to receive specific antivenom and with CK
value at admission. A significant positive correlation was
observed for GFR and diuresis at admission. Correlation
curves are shown in Figures 4, 5, and 6.
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Fig. 6. Positive correlation between urinary volume and GFR at
admission.
FeNa at admission was 2.4 (0.12–19.7%) in patients
who developed ARF, reaching a peak value of 4.1
(0.8–35%). Both FeNa and FEK at admission and at peak
were significantly higher in the ARF group compared to
non-ARF group.
Urinary protein excretion at admission was 34.0
(3.6–160) mg/m2/hr in the ARF group and 9.7 (1.5–95.4)
mg/m2/hr in the non-ARF group (P < 0.0001).
Urinary pH at admission was similar in both groups
[6.5 (5.0–9.0) in ARF and 7.0 (5.0–8.5) in non-ARF, P =
0.17]. In the same way, both groups had similar maximum
pH values [7.5 (5.0–8.5) in ARF and 8.0 (5.5–8.5) in non-
ARF, P = 0.25]. ARF group had a significantly higher
number of leukocytes and red blood cells in urine than
the non-ARF group [10,000 (250–92,000) vs. 6000 (250–
58,000) leukocytes, P = 0.04, and 10,000 (250–68,000) vs.
5000 (250–22,000) red blood cells, P = 0.0077].
Renal function data are summarized in Table 4.
Risk factors for ARF
Two logistic regression models were required to de-
termine risk factors related to the development of ARF
because age and body surface showed a great correlation
and did not allow the analysis of both factors by the same
model. The final results are shown in Table 5.
In both models, time to receive antivenom >2 hours
and CK >2000 U/L at admission were identified as in-
dependent covariates for the development of ARF, and
diuresis >90 mL/hr at admission was identified as a pro-
tection factor against the development of ARF. In the
first model, age <12 years was a risk factor for the devel-
opment of ARF.
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Table 5. Logistic regression: Independent variables associated to
ARF
OR 95% CI P value
Model 1
Age <12 years 5.6 1.20–26.2 0.026
Time to receive antivenom >2 hours 11.1 1.23–101 0.032
CK at admission >2000 U/L 12.7 2.77–58 0.0009
Diuresis at admission >90 mL/hr 0.20 0.0548–0.738 0.014
Model 2
Time to receive antivenom >2 hours 16.8 1.86–151 0.011
CK at admission >2000 U/L 12.3 2.93–51.9 0.0005
Diuresis at admission >90 mL/hr 0.20 0.0602–0.691 0.001
DISCUSSION
The results of this study, the largest prospective analy-
sis of envenomation by South American rattlesnake re-
ported in medical literature, clarify important aspects of
renal impairment caused by crotalid envenomation.
Prevalence of ARF
The prevalence of ARF was extremely high (29%), al-
though the patients were treated at a specialized hospital
and prophylactic measures against myoglobinuria were
used [23]. This prevalence is greater than that reported
for several of the major nephrotoxic drugs, such as amino-
glycoside, amphotericin B, or contrast media [24]. These
data showed that most of the previous studies have under-
estimated the magnitude of the problem, reporting ARF
prevalences of 12.9% to 18.4% after C. durissus snakebite
[1, 19, 20].
It should be noted that the non-ARF group had GFR
at discharge significantly higher than the lowest values
observed during hospitalization, showing that some de-
gree of renal injury might have taken place in almost all
of the patients. The significant recovery of the GFR in al-
most all patients of the ARF group confirmed the acute
nature of the renal insult.
Risk factors for the development of ARF
Antivenom. The heterologous crotalid antivenom
(CAV) used was obtained from equine sensitization. One
milliliter of CAV, which consists mainly of immunoglob-
ulin fragments F(ab′)2, neutralizes 1.5 mg of C. durissus
venom [3]. Circulating venom is not observed one hour
after its administration, and CAV titers remain high up to
24 hours after treatment [25]. The amount to be admin-
istered is determined according to accident classification
(Table 1).
The finding that the delay to administer an adequate
dose of the CAV increases more than 10 times the risk
to develop ARF is not unexpected because the venom
continues to act until it is neutralized. The fact that six of
nine of the patients treated with either incorrect or insuf-
ficient antivenom develop ARF reinforces the extreme
importance of an early and adequate treatment. Recent
data have shown that the CAV prevented proximal tubu-
lar injury in vitro only when it was added simultaneously
with the snake venom [18]. Previous studies have already
suggested there is a correlation between renal injury and
time interval between the snakebite and the administra-
tion of antivenom [9, 20, 26]. The major indication of this
finding is that treatment must be decentralized to allow
an early CAV treatment. Antivenom should be available
in health centers and emergency services of small com-
munities, rather than concentrated in reference hospitals
or services.
A possible factor related to the development of re-
nal injury might be the administration of less CAV in
the ARF group. However, these patients received more
CAV per body surface than the non-ARF group, suggest-
ing that the current recommendation for CAV amount in
severe envenomation cases might be inadequate.
Rhabdomyolysis. Azevedo-Marques et al first
demonstrated that the envenomation by the South
American crotalid induced rhabdomyolysis and myo-
globinuria associated with ARF [7, 8]. Experimental
studies showed that sublethal doses of the venom cause
very early rhabdomyolysis associated with GFR decrease
[13]. It was shown later that crotoxin causes systemic
and selective injury of muscles or skeletal muscle groups
composed of type I and IIa fibers, which are extremely
vascularized and rich in myoglobin [10]. Recent studies
have suggested that calcineurin and nitric oxide pathways
are essential mediators of crotoxin-related myonecrosis
[27, 28].
The clinical diagnosis of rhabdomyolysis is established
when CK increases five or more times above normal lev-
els, with a suggestive clinical picture, and without heart
and/or cerebral injury [22, 29]. In this study, the myotox-
icity of the venom was confirmed by intense and gener-
alized myalgia (100% of the patients), by the complaint
of dark urine (83% of the patients), and by an early and
striking increase of muscle enzymes, especially CK, which
is considered the most sensitive marker of muscle injury
[29]. Although the CK increase was observed in almost
all patients, it was much higher in the ARF group, with an
extremely high peak of the enzyme occurring soon after
the accident.
Rhabdomyolysis is a well-known cause of renal injury
[7, 29] and was strongly related to ARF in this study.
The most effective measure for the prevention of ARF
induced by rhabdomyolysis is extracellular volume ex-
pansion with saline solution combined with sodium bi-
carbonate and mannitol [23, 29]. This solution must be
started early and maintained until myoglobinuria is no
longer present [23]. The volume to be administered is
three to six L/day, when supervision is not assured, or
higher than 10 L/day, when continuous supervision is
available [29]. Indeed, Sakwiwaktul et al, working with
sea snake venom, which has a strong myolytic activity,
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demonstrated that pretreatment with sodium bicarbon-
ate prevented venom-induced renal injury in dogs in the
presence of marked myoglobinuria [30]. In the present
study, volume expansion with alkalinizing solution asso-
ciated with mannitol was not sufficient to prevent uni-
versally ARF, although a pH >6.5, considered ideal to
prevent renal injury by myoglobin, was obtained [3, 23,
31]. The delay to start this maneuver might have con-
tributed for the treatment failure of some patients who
arrived at the hospital later. Another possibility is that
this prophylactic measure was in fact effective, and the
mechanisms leading to ARF are related to direct renal
activity of the venom, causing tubular injury and renal
vasoconstriction [13]. Finally, considering the severity of
the muscle injury shown by CK serum levels, prevention
might have to be more aggressive.
Age. Another independent factor related to ARF in
the multivariate analysis was age <12 years. Indeed, ARF
patients were younger, although the difference was not
statistically significant. Likewise, it was observed that
children have a prevalence of ARF almost three times
higher than adults, although they received more CAV
per body surface, had a higher hydration volume per kg
of body weight, and did not have a longer time interval
from the snakebite to the administration of antivenom
or more intensive rhabdomyolysis than adults (data not
shown). Although children and adults with snakebites
receive equal amounts of CAV [3], children are thought
to be more affected by the venom [32]. Comparatively,
children have a lower blood volume and smaller body
surface, which might be related to a more severe clinical
picture due to an increased concentration of the venom
[32].
This evidence suggests that the amount of antivenom
administered, or the criteria established to calculate its
dose, should be reviewed for children. Prospective and
controlled studies are required for further clarification.
Diuresis. The venom of the South American crotalid
is predominantly excreted by the kidney, and its toxic
components have a direct and indirect activity on renal
cells [13, 22]. A urinary flow of 30 to 40 mL/hr in adults and
1 to 3 mL/kg/hr in children is recommended to prevent
ARF in cases of envenomation by the South American
crotalid [3, 31]. In the present study, diuresis at admission
>90 mL/hr proved to be an independent protective factor
against ARF development. An intense urinary flow might
result in less exposure of renal tubular cells to myoglobin
and to the venom, attenuating the injury and preventing
tubular lumen obstruction by myoglobin cylinders and
cellular remains.
Other factors. The group that developed ARF had a
higher prevalence of severe envenomation. Lid ptosis is
the most important and well-known clinical sign of neu-
rotoxic face [1, 3], and myalgia is one of the most frequent
symptoms reported by victims of crotalid envenomation
[1, 3, 22]. Lid ptosis and myalgia were observed in all ARF
patients in this study, and therefore, it was not possible to
evaluate these variables by logistic regression. Nishioka
and Silveira have described the association of myalgia
and lid ptosis with renal failure in individuals older than
40 years [20]. Dark urine, another severity criterion, was
more frequent in ARF patients, but it was not included in
the logistic regression analysis due to its subjectivity. Ab-
normal CT, one of the criteria used to classify the severity
of the accident, was not significantly associated with ARF
in the multivariate analysis.
Other factors that might be related to the genesis of
ARF, such as shock, hypotension, hemolysis, sepsis, or
the use of nephrotoxic drugs were not observed in these
patients.
ARF characteristics
ARF occurred early, within the first 24 to 48 hours af-
ter the accident, suggesting the direct nephrotoxicity of
the venom shown experimentally might also be clinically
present. The majority of cases were nonoliguric.
FeNa values in ARF patients were significantly higher
than in patients who did not have ARF, reaching a max-
imum value of 4%, suggesting there was proximal renal
tubular cell injury. The use of loop diuretics does not seem
to have increased FeNa because only 14% of the patients
who developed ARF had used furosemide. The amount
of proteinuria observed in the ARF group also suggests
the presence of tubular injury, although the possibility of
some degree of glomerular injury might not be ruled out
[33]. These findings are consistent with the description of
acute tubular necrosis in biopsies and autopsies of victims
of the South America crotalid snakebite [7, 34].
Increased FeK in ARF patients probably indicates
an increase in the distal tubular secretion of potassium
caused by an increased distal delivery of sodium, due to
the decreased proximal tubular reabsorption of sodium.
These data suggest the distal areas of the nephron are
preserved.
Dialysis treatment was indicated in 24% of the cases.
Previous studies have reported a greater demand for dial-
ysis, ranging from 68% to 77% of the patients. This dis-
crepancy is probably related to the low specificity of ARF
diagnostic criteria used in these studies, only identifying
the more severe cases of renal injury [14, 20, 34].
Renal function was recovered in the individuals who
survived ARF. Even though, GFR values at discharge of
these patients were significantly lower than GFR values
for the patients without ARF, indicating there might have
been an incomplete recovery of the glomerular filtration
rate in the studied period. The late follow-up of renal
function in these individuals would be very important,
but is extremely difficult to accomplish because most of
the patients live in faraway rural areas.
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ARF caused a longer hospitalization time, most likely
resulting in higher costs and more use of hospital
resources.
The reported mortality for ARF after envenomation
by the tropical rattlesnake is expressive and ranges from
8% to 17%, depending on the studied series [14, 20, 34].
In this study, the mortality rate of 10% is quite signif-
icant because it involved young and previously healthy
individuals.
CONCLUSION
ARF after envenomation by C. durissus has a high
prevalence (29%) and is related to significant mortality
in young and healthy patients. A delay in the administra-
tion of specific antivenom, presence of CK >2000 U/L,
and age <12 years were independent risk factors for ARF.
Diuresis >90 mL/hr at admission was a protective factor.
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